Garden City Group raises $49,000 for Leukemia & Lymphoma Society
A year's worth of fundraisers concluded this week when the Garden City Group (GCG), one of the largest claims administration firms in the United States, donated the aggregate total of $49,000 to its chosen charity, the Leukemia & Lymphoma Society (LLS).
Employees of GCG (a leader in legal administration services for claims administrations such as class action lawsuits) spent the year involved in a variety of fundraisers dedicated to the LLS, including pep rallies, bake sales, sports tournaments, raffles and jeans days, among others. They also participated in the LLS' annual 'Light The Night Walk'.
Said David Isaac, chief executive officer of GCG, "These terrible diseases affect families everywhere, and we hope that our Company's support and contributions will help in working towards LLS's mission."
Source: PR Newswire
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
